Novavax, Inc. (NASDAQ:NVAX) has been given a consensus rating of “Hold” by the twelve brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $3.16.
NVAX has been the subject of a number of recent analyst reports. Citigroup Inc. raised Novavax from a “neutral” rating to a “buy” rating and set a $2.00 target price for the company in a report on Tuesday, October 31st. BidaskClub lowered Novavax from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Ladenburg Thalmann Financial Services raised Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price objective for the company in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price objective on shares of Novavax in a report on Friday, July 21st.
In related news, Director James F. Young sold 175,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.00% of the company’s stock.
A number of hedge funds have recently made changes to their positions in NVAX. Raymond James Financial Services Advisors Inc. lifted its position in Novavax by 49.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 29,800 shares during the last quarter. Profund Advisors LLC lifted its position in Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 455 shares during the last quarter. Voya Investment Management LLC lifted its position in Novavax by 18.6% in the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 21,639 shares during the last quarter. HighTower Advisors LLC lifted its position in Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 5,250 shares during the last quarter. Finally, American International Group Inc. increased its stake in shares of Novavax by 7.1% during the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 10,965 shares during the period. Hedge funds and other institutional investors own 44.81% of the company’s stock.
Shares of Novavax (NVAX) traded up $0.01 on Friday, reaching $1.14. The company had a trading volume of 2,721,008 shares, compared to its average volume of 3,821,095. Novavax has a 52 week low of $0.73 and a 52 week high of $1.78. The company has a quick ratio of 3.54, a current ratio of 3.54 and a debt-to-equity ratio of -5.37.
Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.16). The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The company’s quarterly revenue was up 168.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.29) EPS. sell-side analysts expect that Novavax will post -0.62 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Novavax, Inc. (NVAX) Receives Consensus Rating of “Hold” from Brokerages” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/05/novavax-inc-nvax-receives-consensus-rating-of-hold-from-brokerages.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
What are top analysts saying about Novavax Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novavax Inc. and related companies.